Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ikke-invasiv mediannervestimulering for at dæmpe atrielle takyarytmier efter kateterablation for atrieflimren (NEUROPULSE)

6. november 2026 opdateret af: Vivek Reddy, Icahn School of Medicine at Mount Sinai

Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.

The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:

  1. early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
  2. AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).

The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).

Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).

In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.

Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.

Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

51

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mount Sinai

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  • Men and women ages ≥18 years
  • Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
  • Ability and willingness to sign an informed consent form.
  • Ability and willingness to use CardiaCare RR2 device, continuous ECG monitoring, and has an available SmartPhone.

Exclusion Criteria

  • Rheumatic heart disease
  • Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
  • Moderate to severe mitral stenosis or history of mitral valve replacement
  • Pacemaker or CRTD or any implanted electrical stimulating device
  • Unilateral or bilateral vagotomy
  • Peripheral neuropathy affecting the tested upper extremity.
  • Severe heart failure (New York Heart Association Class III or IV) within 90 days.
  • Recent (within 90 days) stroke or transient ischemic attack.
  • Recent (within 90 days) myocardial infarction.
  • Pregnancy or breast feeding.
  • Life expectancy <1 year for any medical condition
  • Currently enrolled in another study that would interfere with this study
  • Unsuitable for participating in the study according to attending physician

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Participants with CardiaCare RR2

Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users.

CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.

Sham-komparator: Participants with Sham Device

Sham device will be dispensed, which will create a sensation but not provide therapy

Sham device will be dispensed, which will create a sensation but not provide therapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
AF/AFL occurrence
Tidsramme: at 2-months and 6-months post-ablation procedure

Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG.

at 2-months and 6-months post-ablation procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antal skadestuebesøg
Tidsramme: 6 måneder efter ablation
6 måneder efter ablation
Antal indlæggelser
Tidsramme: 6 måneder efter ablation
6 måneder efter ablation
Antal Cardioversioner
Tidsramme: 6 måneder efter ablation
6 måneder efter ablation
Antal ablationsgentagelser
Tidsramme: 6 måneder efter ablation
6 måneder efter ablation
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Tidsramme: 2-month and 6-month post-ablation procedure

Time to first AT or AF recurrence measured by CardiaCare RR2

2-month and 6-month post-ablation procedure
Number of arrythmia occurrences
Tidsramme: 2-month and 6-month post-ablation procedure

Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG.

2-month and 6-month post-ablation procedure
Number of Atrial Arrythmia Symptoms
Tidsramme: 6-month post-ablation procedure

Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation.

6-month post-ablation procedure
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Tidsramme: 6 months post-ablation

Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation.

6 months post-ablation
Quality of Life measured using The European Heart Rhythm Association (EHRA) score
Tidsramme: Baseline, 2-months, and 6-months

The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms.

Baseline, 2-months, and 6-months
Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score
Tidsramme: Baseline, 2-months, and 6-months

The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens.

Baseline, 2-months, and 6-months
Change in PAC/AT/AFL before and after treatment with RR2
Tidsramme: Baseline and 6-month post-ablation

Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device.

Baseline and 6-month post-ablation
Change in Heart Rate Variability (HRV)
Tidsramme: Baseline and 6-month post-ablation

Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience.

Baseline and 6-month post-ablation

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai
  • Ledende efterforsker: Mohit Turagam, MD, Icahn School of Medicine at MS

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. oktober 2024

Primær færdiggørelse (Faktiske)

30. juli 2026

Studieafslutning (Faktiske)

30. juli 2026

Datoer for studieregistrering

Først indsendt

19. december 2024

Først indsendt, der opfyldte QC-kriterier

19. december 2024

Først opslået (Faktiske)

27. december 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • STUDY-24-00641

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .